GC101 is currently in clinical trials — not yet approved for commercial use. Participation in trials provides free treatment under close medical supervision.
ASCO 2026 LBA · GC101 Phase II melanoma trial meets primary endpoint: 4.3 mo PFS (HR=0.43), 42% ORR, zero treatment-related deaths. Read more →
Independent Patient Advisory

When standard treatment
has run out of road,
TIL therapy may offer a path.

If you or a loved one has advanced cancer that is no longer responding to standard treatments, cell therapy in China may offer a path forward. CancerPath helps international patients access GC101 TIL therapy clinical trials with response rates over 40% in lung cancer and melanoma.

Check your eligibility Learn how it works
41.7%
Objective response rate
in advanced NSCLC (Ib trial)
66.7%
12-month overall survival
in advanced NSCLC
35%+
Response rate across
multiple solid tumors
>4 yrs
Longest documented
tumor-free survival
The science

What is TIL therapy?

TIL (Tumor-Infiltrating Lymphocyte) therapy uses your own immune cells — already trained to recognize your tumor — amplified millions of times and returned to fight the cancer.

01

Your cells, your targets

TIL cells live inside your tumor. Unlike CAR-T or checkpoint inhibitors, they're already sensitized to your specific cancer's antigens — no genetic engineering required.

02

GC101's breakthrough

Traditional TIL requires intensive chemotherapy and high-dose IL-2 injections. GC101 eliminates both — making it safer, more accessible, and suitable for patients who couldn't tolerate conventional TIL.

03

One infusion, lasting effect

A single IV infusion. Multiple patients have achieved complete tumor clearance (CR), with the longest tumor-free survival exceeding 4 years and counting.

Scientific Leadership

Clinical trials led by
world-class investigators

Each GC101 and GC203 clinical trial is led by a leading Chinese oncologist with international recognition in their field.

SL

Shun Lu (陆舜)

MD, PhD — Thoracic Oncology

Shanghai Chest Hospital

PI, MIZAR-005 — GC101 in advanced NSCLC

Learn more →

JG

Jun Guo (郭军)

MD, PhD — Melanoma & Sarcoma

Peking University Cancer Hospital

PI, MIZAR-003 — GC101 in advanced melanoma

Learn more →

XW

Xiaohua Wu (吴小华)

MD, PhD — Gynecologic Oncology

Fudan University Shanghai Cancer Center

PI, GC203 — TIL therapy for ovarian cancer

Learn more →

Why GC101

6 things GC101 doesn't require

Developed by Juncell Therapeutics, GC101 is the world's first natural TIL therapy without high-intensity lymphodepletion or IL-2 administration.

✕

High-dose IL-2

Eliminates the severe toxicity associated with traditional TIL protocols

✕

Feeder cells in culture

No donor-derived support cells needed in manufacturing

✕

Viral gene modification

Natural TIL — no virus-mediated engineering, lower biosafety concerns

✕

Intensive lymphodepletion

Only mild conditioning required before infusion — no aggressive chemo

✕

Sterile ward admission

No requirement for intensive care unit or specialized isolation room

✕

Post-infusion IL-2

No follow-up IL-2 injections needed after cell infusion

Who can be treated

Current indications

GC101 has shown responses across multiple solid tumors. Active clinical trials are recruiting now.

Key Phase II — Recruiting

Melanoma (MIZAR-003)

For patients who have failed PD-1 therapy. Multi-center randomized trial at top institutions including Peking University Cancer Hospital.

Phase Ib — Recruiting

Non-small cell lung cancer (MIZAR-005)

For patients who have failed targeted therapy + platinum chemotherapy, or PD-(L)1 + platinum chemo. PI: Prof. Lu Shun, Shanghai Chest Hospital.

Phase I — Exploring

Ovarian & gynecologic cancers

GC203 (gene-modified TIL) showing promising results in multi-line treatment failures. Eligible patients can enquire.

Early Stage

Other solid tumors

Including cervical cancer, endometrial cancer, pancreatic cancer, and glioblastoma. Clinical cases with objective responses documented.

The process

What the treatment journey looks like

From first contact to cell infusion, here's a realistic picture of the timeline and logistics involved.

1

Eligibility screening

Complete our online screener or contact us directly. We review your diagnosis, treatment history, and current status to assess whether you meet clinical trial criteria.

Remote / online
2

Medical review & enrollment

If eligible, Juncell's clinical team reviews your case. You'll need to provide recent imaging, blood work, pathology, and treatment history. Enrollment is at no cost.

Remote document submission
3

Tumor tissue collection (Shanghai)

A minimally invasive biopsy procedure is performed at the lead trial center in Shanghai to collect tumor tissue. This is the source material for manufacturing your TIL cells. Stay: approximately 3–5 days.

Trip 1 — Shanghai
4

Cell manufacturing (4–6 weeks)

Your tumor tissue is transported to Juncell's GMP manufacturing facility. TIL cells are expanded from millions to billions over approximately 4–6 weeks. You return home during this period.

Wait at home
5

Conditioning & infusion (Hainan)

You return to China for mild pre-conditioning chemotherapy, followed by IV infusion of your TIL cells. Hospital stay: approximately 2–3 weeks in Hainan Boao.

Trip 2 — Hainan
6

Response assessment (ongoing)

First imaging assessment at 6 weeks post-infusion. Follow-up assessments every 6 weeks. Remote follow-up can often be coordinated with your home oncologist.

Mostly remote
Free eligibility check

Is this treatment right for you?

Answer 7 quick questions to find out if you or your loved one may qualify for GC101 clinical trials. Takes about 2 minutes.

Question 1 of 7
What type of cancer has been diagnosed?
Non-small cell lung cancer (NSCLC)
Melanoma
Other solid tumor (cervical, ovarian, pancreatic, glioblastoma, etc.)
Question 2 of 7
Is the patient between 18 and 75 years old?
Yes
No (under 18 or over 75)
Question 3 of 7
Has the patient failed at least one prior line of systemic treatment?
For NSCLC: targeted therapy + platinum chemo failure, or PD-(L)1 + platinum chemo failure required.
Yes — failed at least one systemic treatment (targeted, immunotherapy, or chemotherapy)
No — treatment-naive or still responding to first-line therapy
Question 4 of 7
How would you describe the patient's current functional status?
ECOG 0 = fully active; ECOG 1 = restricted but ambulatory, self-care possible
Mostly normal daily activity, able to care for themselves (ECOG 0–1)
Significant fatigue, needs considerable bed rest or assistance (ECOG 2+)
Question 5 of 7
Is there a tumor lesion accessible for a minor biopsy procedure?
TIL therapy requires a small tumor tissue sample to manufacture your cells. Typically a minimally invasive procedure.
Yes — accessible lesion and patient is fit enough for a small procedure
No accessible lesion, or patient cannot tolerate any surgery
Question 6 of 7
Does the patient have any of the following conditions?
None of the below
Pulmonary fibrosis, interstitial lung disease, unstable brain metastases, active major infection, or severe organ dysfunction
Question 7 of 7
Is the patient open to participating in a clinical trial?
GC101 is not yet commercially approved. Clinical trial participation means free treatment, close monitoring, and care by leading oncologists.
Yes — willing to explore clinical trial options
Not sure / prefer not to participate in trials
Likely eligible
You may qualify for MIZAR-005 (NSCLC trial)
Based on your responses, the patient appears to meet the key inclusion criteria for GC101's lung cancer clinical trial. The next step is a formal medical review by Juncell's clinical team.

Please prepare the following before reaching out:
① Recent imaging (CT/PET — ideally viewable digitally)
② Recent blood count and biochemistry reports
③ Infectious disease screening (HBV, HCV, HIV)
④ Full treatment history with responses
Contact Juncell clinical team
Email: clinicaltrials@juncell.com
Phone: +86 21-69990503
WeChat: 18019732895 (Dr Zhang) · 18001759113 (Dr Cheng)

CancerPath advisory
Email: clinicaltrials@juncell.com
Start over
Potentially eligible
Ask about MIZAR-003 (melanoma trial)
The melanoma Key Phase II trial (MIZAR-003) has met its primary enrollment target, but residual spots may exist. Contact Juncell directly to check current availability.

Key requirement: PD-1 therapy failure or intolerance, at least 2 lesions, physically able to undergo minor biopsy surgery.
Email: clinicaltrials@juncell.com
Phone: +86 21-69990503
WeChat: 18019732895 · 18001759113
Start over
Worth enquiring
No active registered trial for this cancer type — but ask
GC101 has documented responses in cervical cancer, endometrial cancer, glioblastoma, and pancreatic cancer. These fall under expanded access or investigator-initiated trials. Contact Juncell to ask about compassionate use or expanded access options.
Email: clinicaltrials@juncell.com or contact@juncell.com
Questions? Contact us via the form below.
Start over
Likely ineligible at this time
Based on your responses, the patient may not meet current criteria
The likely reason is one of: age outside 18–75, poor functional status (ECOG ≥ 2), an exclusion condition (pulmonary fibrosis, unstable brain metastases), or no accessible lesion for biopsy.

We still recommend contacting Juncell directly — some cases qualify on individual medical assessment even when screening suggests otherwise. Also ask about the "seed cell cryopreservation" option if the patient is in remission now but may relapse later.
Email: clinicaltrials@juncell.com
Questions? Contact us via the form below.
Start over
Worth understanding first
Clinical trials aren't what most people think
Many patients hesitate because they associate trials with being a "guinea pig." GC101 has already completed Phase I safety validation — this phase is about confirming efficacy, not testing for unknown risks.

Participating means: free treatment from top oncologists, close monitoring, and access to a therapy with documented 40%+ response rates that you couldn't otherwise access. There's no obligation — contact us to learn more first.
Our advisor will be copied on all responses.
Juncell clinical team: clinicaltrials@juncell.com
Start over
Clinical cases

Real patients, documented responses

These are published clinical cases from Juncell's ongoing trials — not anecdotes, but formally assessed outcomes.

Acral melanoma · Multi-site metastases

9cm foot lesion, lung and abdominal spread — PR at 18 weeks

Patient had failed PD-1 monotherapy and dual immunotherapy. Foot lesion reduced 36%, lung lesion reduced 47.4%, abdominal lesion reduced 31.7%. No major adverse events — only mild rash and fever, resolved with standard treatment.

Partial response (PR)
Advanced NSCLC · Multi-line failure

41.7% ORR in patients with median 3 prior treatment lines

Phase Ib data from MIZAR-005 predecessor. 12-month overall survival rate 66.7% with median OS not yet reached at 13 months follow-up. DCR 66.7%.

Phase Ib cohort data
High-grade glioblastoma

Single IV infusion — complete tumor clearance at 4 weeks

Documented case from investigator-initiated study. Single infusion without IL-2 or intensive conditioning. Tumor undetectable on imaging at 4-week assessment.

Complete response (CR)
Common questions

What people ask us

What does this cost? ↓
Participation in an active clinical trial is free — there is no charge for the GC101 treatment itself. You will need to cover travel, accommodation, and living costs for your time in China. CancerPath's advisory services for coordinating the referral process are also free. We earn a referral coordination fee from Juncell, not from patients.
Do I need to speak Chinese? ↓
No. Juncell's clinical coordinators handle international patients in English. CancerPath can also help with translation of medical documents and liaison with the clinical team throughout the process.
How long do I need to be in China? ↓
Typically two trips. Trip 1 (tumor biopsy in Shanghai): approximately 3–5 days. Then you return home for 4–6 weeks while cells are manufactured. Trip 2 (conditioning + infusion, Hainan): approximately 2–3 weeks. Follow-up can largely be managed with your home oncologist via imaging and report sharing.
Is GC101 approved? ↓
GC101 is currently in Phase II clinical trials approved by China's NMPA. It is not yet commercially approved for sale. The melanoma Key Phase II trial (MIZAR-003) has met enrollment targets; the lung cancer Ib trial (MIZAR-005) is actively recruiting. Commercial approval application is expected in 2026.
What if I'm in remission now — is it too late? ↓
Not necessarily. Juncell has developed a "seed cell cryopreservation" technique — tumor tissue collected now can be banked, and TIL cells manufactured at a later date when needed (proven viable for up to 2 years). If you've had recent surgery, it may be worth exploring whether tissue was archived.
How is CancerPath different from a medical tourism agency? ↓
We don't organize travel packages or earn from logistics. We're an independent advisory that helps patients understand whether they qualify, prepares them for the clinical process, and connects them to Juncell's clinical team. We're transparent about our referral fee arrangement and do not recommend treatment we don't believe in.
Get in touch

Talk to an advisor

If you'd like a personal conversation before filling out any form, just email us. We respond within 48 hours and can arrange a call in English, French, or Mandarin.

Email clinicaltrials@juncell.com
Response Within 48 hours
Languages English · French · Mandarin
Partner Juncell Therapeutics ↗

CancerPath is an independent patient advisory service. We are not a healthcare provider and do not give medical advice. All treatment decisions should be made with your oncologist.

By submitting you agree to being contacted by a CancerPath advisor. We never share your information with third parties without consent.

Thank you for reaching out

A CancerPath advisor will review your information and be in touch within 48 hours. Please check your spam folder if you don't hear from us.

Clinical partner
Juncell Therapeutics (君赛生物) — Shanghai